BR112023000455A2 - Tratamento de doença inflamatória que usa anticorpos de fator antitecidual - Google Patents

Tratamento de doença inflamatória que usa anticorpos de fator antitecidual

Info

Publication number
BR112023000455A2
BR112023000455A2 BR112023000455A BR112023000455A BR112023000455A2 BR 112023000455 A2 BR112023000455 A2 BR 112023000455A2 BR 112023000455 A BR112023000455 A BR 112023000455A BR 112023000455 A BR112023000455 A BR 112023000455A BR 112023000455 A2 BR112023000455 A2 BR 112023000455A2
Authority
BR
Brazil
Prior art keywords
tissue factor
treatment
antibodies
inflammatory disease
factor antibodies
Prior art date
Application number
BR112023000455A
Other languages
English (en)
Inventor
Migone Thi-Sau
Greene William
Original Assignee
Iconic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iconic Therapeutics Inc filed Critical Iconic Therapeutics Inc
Publication of BR112023000455A2 publication Critical patent/BR112023000455A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

TRATAMENTO DE DOENÇA INFLAMATÓRIA QUE USA ANTICORPOS DE FATOR ANTITECIDUAL. São fornecidos no presente documento anticorpos que se ligam especificamente a Fator Tecidual humano (FT), conjugados anticorpo-fármaco (ADCs) anti-FT e composições que compreendem os anticorpos ou ADCs para tratamento de doenças inflamatórias. Também são fornecidos no presente documento métodos de tratamento de indivíduos que têm doenças inflamatórias administrando-se os anticorpos ou ADCs anti-FT.
BR112023000455A 2020-07-10 2021-07-10 Tratamento de doença inflamatória que usa anticorpos de fator antitecidual BR112023000455A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063050629P 2020-07-10 2020-07-10
PCT/US2021/041192 WO2022011324A1 (en) 2020-07-10 2021-07-10 Inflammatory disease treatment using anti-tissue factor antibodies

Publications (1)

Publication Number Publication Date
BR112023000455A2 true BR112023000455A2 (pt) 2023-03-28

Family

ID=79552117

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023000455A BR112023000455A2 (pt) 2020-07-10 2021-07-10 Tratamento de doença inflamatória que usa anticorpos de fator antitecidual

Country Status (12)

Country Link
EP (1) EP4178608A1 (pt)
JP (1) JP2023534191A (pt)
KR (1) KR20230037042A (pt)
CN (1) CN116322713A (pt)
AU (1) AU2021304359A1 (pt)
BR (1) BR112023000455A2 (pt)
CA (1) CA3184987A1 (pt)
CL (1) CL2023000099A1 (pt)
IL (1) IL299632A (pt)
MX (1) MX2023000499A (pt)
TW (1) TW202216198A (pt)
WO (1) WO2022011324A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202342517A (zh) * 2022-01-12 2023-11-01 美商艾康尼醫療有限責任公司 使用抗組織因子抗體之炎性疾病治療
WO2023160651A1 (zh) * 2022-02-24 2023-08-31 苏州信诺维医药科技股份有限公司 一种抗体及其药物偶联物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001250814B2 (en) * 2000-03-16 2007-02-15 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US20060104944A1 (en) * 2004-11-18 2006-05-18 Mousa Shaker A Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use
NZ568762A (en) * 2005-11-07 2011-11-25 Scripps Research Inst Use of an inhibitor of tissue factor signaling in the manufacture of a medcament for inhibiting or suppressing tissue factor/tissue factor VIIa signaling involving protease activated receptor 2 in a mammal
UA109633C2 (uk) * 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
US8722044B2 (en) * 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
KR20200118029A (ko) * 2018-01-04 2020-10-14 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법

Also Published As

Publication number Publication date
CA3184987A1 (en) 2022-01-13
CL2023000099A1 (es) 2023-08-11
EP4178608A1 (en) 2023-05-17
WO2022011324A1 (en) 2022-01-13
AU2021304359A1 (en) 2023-03-02
MX2023000499A (es) 2023-04-20
CN116322713A (zh) 2023-06-23
JP2023534191A (ja) 2023-08-08
TW202216198A (zh) 2022-05-01
IL299632A (en) 2023-03-01
KR20230037042A (ko) 2023-03-15

Similar Documents

Publication Publication Date Title
BR112018075198A2 (pt) método para o tratamento de câncer ou uma doença associada a patógeno, composição farmacêutica, e kit
AR059922A1 (es) Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
MX2022002592A (es) Conjugado de anticuerpo-farmaco que comprende un anticuerpo contra el gen del receptor huerfano 1 similar a tirosina cinasa receptora (ror1) humano y uso para el mismo.
CR10244A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
UA109633C2 (uk) Антитіло людини проти тканинного фактора
BR112023000455A2 (pt) Tratamento de doença inflamatória que usa anticorpos de fator antitecidual
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
GT201200318A (es) Anticuerpos hacia gdf8 humano
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
RU2018123717A (ru) Комбинированные лечения, их применения и способы
PH12020551037A1 (en) Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
BR112019023249A8 (pt) anticorpos monoclonais igf-1r e usos dos mesmos
ECSP088241A (es) Un conjugado citotóxico ca6 antígeno-específico y métodos para utilizar el mismo
MX2021010453A (es) Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos.
BR112018002436A2 (pt) tratamento de combinação de usos de métodos destes
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
BR112021019107A2 (pt) Anticorpos contra amiloide-beta piroglutamato e usos dos mesmos
EA202092518A1 (ru) Композиции и способы лечения рака
BR112022005423A2 (pt) Interrupção de tecidos tumorais por alvejamento de proteína de ativação de fibroblasto (fap)
BR0210648A (pt) Variante de uma molécula imunointerativa, anticorpo monoclonal, forma disimunizada de anticorpo monoclonal 3b6, método para a geração de um anticorpo monoclonal desimunizado, molécula de anticorpo desimunizada, anticorpo desimunizado, anticorpo monoclonal de murino variante 3b6 desimunizado, variante de um anticorpo monoclonal de murino 3b6 desimunizado para uso em humanos, método para a detecção de um coágulo sanguìneo em um paciente humano, método para a detecção de um coágulo sanguìneo ou de um seu fragmento de ligação a antìgeno, método para a facilitação da dissolução ou da remoção de um coágulo sanguìneo em um humano, uso de um anticorpo monoclonal derivado de murino variante, e, conjugado
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
BR112019011350A2 (pt) terapia de combinação
BR112022019853A2 (pt) Imunoconjugado que se liga especificamente a eno-1, composição para diagnóstico ou imagem de células ou de um tecido que expressa eno-1, composição farmacêutica para uso no tratamento de uma doença inflamatória, método para tratar uma doença inflamatória, e uso do imunoconjugado
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina